Based on the key indicators related to ANI Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, ANI Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in July. At this time, ANI Pharmaceuticals' Cash is relatively stable compared to the past year. As of 06/22/2025, Non Current Assets Total is likely to grow to about 793.8 M, while Common Stock is likely to drop 1,710. Key indicators impacting ANI Pharmaceuticals' financial strength include:
Investors should never underestimate ANI Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor ANI Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in ANI Pharmaceuticals.
Understanding current and past ANI Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of ANI Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in ANI Pharmaceuticals' assets may result in an increase in income on the income statement.
ANI Pharmaceuticals competes with Phibro Animal, Prestige Brand, Alkermes Plc, Dr Reddys, and Collegium Pharmaceutical. ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota. ANI Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 601 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what ANI Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining ANI Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare ANI Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ANI Pharmaceuticals competition to find correlations between indicators driving ANI Pharmaceuticals's intrinsic value. More Info.
ANI Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, ANI Pharmaceuticals' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value ANI Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
ANI Pharmaceuticals Systematic Risk
ANI Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ANI Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on ANI Pharmaceuticals correlated with the market. If Beta is less than 0 ANI Pharmaceuticals generally moves in the opposite direction as compared to the market. If ANI Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one ANI Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ANI Pharmaceuticals is generally in the same direction as the market. If Beta > 1 ANI Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in ANI Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ANI Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of ANI Pharmaceuticals growth as a starting point in their analysis.
ANI Pharmaceuticals June 22, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of ANI Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of ANI Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of ANI Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing ANI Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ANI Pharmaceuticals's daily price indicators and compare them against related drivers.
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.